Dr. Gordon DeWald, professor emeritus in laboratory medicine and laboratory genetics at Mayo Clinic, provides an overview of his study (http://tinyurl.com/mcce2t) [...]
ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood. https://www.youtube.com/watch?v=biPY4-SkYbk Journalists: Sound bites with Dr. Feldman are available in the downloads. Patients whose lymphomas had TP63 rearrangements had only a 17 percent chance of living five years beyond diagnosis, compared to 90 percent of patients whose tumors had DUSP22 rearrangements. A third group of tumors, those with neither rearrangement, was associated with an intermediate survival rate.